Thoma Bravo has completed its buy of MedeAnalytics, a provider of cloud-based financial performance analytics for the healthcare industry. Current investors Bain Capital Ventures and Emergence Capital Partners remain as minority shareholders.
MedeAnalytics is used by healthcare companies to analyze patient data to improve financial performance by strengthening core operations and improving the quality of patient care. MedeAnalytics’ cloud-based tools have been used by over 1,500 hospitals, health systems, health plans, and state Medicaid programs. The company is led by its CEO Andy Hurd and is headquartered north of Oakland in Emeryville, CA (www.medeanalytics.com).
“Now more than ever, healthcare providers and hospital systems alike are under pressure to rein in costs and demonstrate value to their customers and patients,” said Scott Crabill, managing partner at Thoma Bravo. “MedeAnalytics has the products and expertise to help healthcare institutions sift through vast amounts of data and deliver cost-effective care.”
Thoma Bravo provides equity and strategic support to management teams building growing companies. The firm originated the concept of industry consolidation investing, which seeks to create value through the strategic use of acquisitions to accelerate business growth. Thoma Bravo currently manages approximately $8.5 billion of equity capital.
“We’ve been working with MedeAnalytics’ management team to set a plan for growth and enhanced market leadership moving forward,” said Arvindh Kumar, principal at Thoma Bravo. “With the transaction closed, we look forward to working with the team to realize MedeAnalytics’ strategic growth objectives.”
Thoma Bravo was founded in 1981 and has offices in Chicago and San Francisco (www.thomabravo.com).
© 2015 PEPD • Private Equity’s Leading News Magazine • 9-30-15
